Universal CAR-T Cells Targeting AML — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Universal CAR-T Cells Targeting AML — Stella

Recruiting

Back to Acute Myeloid Leukemia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong

Key details

Phase

Early testing

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment target

~30 participants

Started

October 2023

Primary completion

September 2026

Age range

6 Months – 75 Years

Last updated October 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov